Verrica Pharmaceuticals (VRCA) Total Current Liabilities (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Total Current Liabilities of $16.2 million for Q1 2026, down 44.83% year-over-year from $29.4 million in Q1 2025, and down 1.33% quarter-over-quarter from $16.4 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Total Current Liabilities (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $16.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 44.83% year-over-year to $16.2 million; the TTM figure through Mar 2026 stood at $16.2 million (down 44.83% YoY), while the FY2025 annual figure was $16.4 million, down 43.34% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $16.2 million, down from $16.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $45.7 million in Q2 2022, with the low at $2.6 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $19.4 million (2024), against an average of $20.2 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities slumped 94.1% in 2023, then jumped 632.69% in 2024.
- Verrica Pharmaceuticals' Total Current Liabilities stood at $3.5 million in 2022, then soared by 392.17% to $17.0 million in 2023, then soared by 70.42% to $29.0 million in 2024, then slumped by 43.34% to $16.4 million in 2025, then dropped by 1.33% to $16.2 million in 2026.
- Business Quant data shows VRCA's Total Current Liabilities at $16.2 million in Q1 2026, $16.4 million in Q4 2025, and $28.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Verrica Pharmaceuticals | 104.71 Mn | 93.51 Mn | - | 22.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.44 Mn |
| Mar 31, 2026 | 16.22 Mn |
| Dec 31, 2025 | 16.44 Mn |
| Sep 30, 2025 | 28.91 Mn |
| Jun 30, 2025 | 29.22 Mn |
| Mar 31, 2025 | 29.40 Mn |
| Dec 31, 2024 | 29.01 Mn |
| Sep 30, 2024 | 21.03 Mn |
| Jun 30, 2024 | 20.05 Mn |
| Mar 31, 2024 | 19.37 Mn |
| Dec 31, 2023 | 17.02 Mn |
| Sep 30, 2023 | 11.37 Mn |
| Jun 30, 2023 | 5.73 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 3.46 Mn |
| Sep 30, 2022 | 3.08 Mn |
| Jun 30, 2022 | 45.71 Mn |
| Mar 31, 2022 | 44.80 Mn |
| Dec 31, 2021 | 46.06 Mn |
| Sep 30, 2021 | 46.37 Mn |